Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Randy Noelle
Dartmouth College, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
ImmuNext Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
ImmuNext is developing novel therapeutics that modulate the immune system to treat cancer and autoimmune diseases. This research project studies a molecule which ImmuNExt has licensed.
Given Dr. Noelle's role as Co-Investigator in this project, his financial interest in ImmuNext (equity and consulting income as described above) could significantly and directly affect the design, conduct, and reporting of the research.
Negative regulation of Lupus by the VISTA Pathway
Narrative. Systemic lupus erythematosus (SLE, lupus) is an autoimmune disease commonly affecting women in young adulthood. SLE has protean manifestations, the most devastating of which are renal and CNS involvement, both associated with high morbidity and mortality. Although truly extraordinary advances have been made in the treatment of other autoimmune diseases, such as rheumatoid arthritis and ANCA- associated vasculitis, the treatment for lupus remains chemotherapy-based, for the most part effective, but also very toxic. There is clearly an ongoing unmet need for an effective, safe ?biologic? for the treatment of lupus.
Filed on February 14, 2017.
Tell us what you know about Randy Noelle's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Randy Noelle”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Randy Noelle | Dartmouth College | Conflict of Interest | ImmuNext Inc. | >$600,000 |
| Randy Noelle | Dartmouth College | Conflict of Interest | ImmuNext Inc | >$600,000 |
| Randy Noelle | Dartmouth College | Conflict of Interest | ImmuNext Inc | >$600,000 |
| Randy Noelle | Dartmouth College | Conflict of Interest | ImmuNext Inc. | >$600,000 |
| Randy Noelle | Dartmouth College | Conflict of Interest | ImmuNext Inc. | $40,000 - $59,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.